Dosing Recommendation for Mild Hyperkalemia with Lokelma
For a patient with mild hyperkalemia (K+ 5.3 mmol/L) and severe CKD not on dialysis, start with the standard correction dose of Lokelma 10 g three times daily for up to 48 hours, as this is the FDA-approved dosing regimen regardless of hyperkalemia severity. 1
Rationale for Standard Dosing
The FDA label is unequivocal: the recommended dose for initial treatment of hyperkalemia is 10 g administered three times daily for up to 48 hours, without stratification by severity 1. This applies to your patient despite the "mild" elevation at 5.3 mmol/L.
Why Not Start Lower?
Clinical trial data support the 10 g TID regimen: In the pivotal phase 3 studies, SZC 10 g three times daily achieved normokalaemia in 98% of patients within 48 hours, with a mean reduction of approximately 1.1 mmol/L 2, 3
Lower doses are less effective for correction: The dose-response data show that 2.5 g and 5 g doses produced significantly smaller potassium reductions (0.5 mmol/L) compared to 10 g (0.7 mmol/L) at 48 hours 4
Your patient has high-risk features: With eGFR 11 mL/min, this patient is at substantial risk for recurrent hyperkalemia and needs reliable, rapid correction to enable continuation of any RAASi therapy 5
Practical Implementation
Correction Phase (Days 1-2):
- Lokelma 10 g three times daily for 48 hours
- Check potassium at 24-48 hours to confirm normokalaemia (3.5-5.0 mmol/L)
Maintenance Phase (Day 3 onward):
- Once normokalaemic, transition to 10 g once daily 1
- Monitor potassium weekly initially, then adjust dose in 5 g increments based on levels
- Maintenance range: 5 g every other day to 15 g daily 1
Important Caveats
Sodium load consideration: Each 5 g dose contains ~400 mg sodium 1. With severe CKD (eGFR 11), monitor for edema, though this was primarily seen at the 15 g daily maintenance dose in trials 2. The 2025 European guidance emphasizes that potassium binders enable RAASi continuation, which improves outcomes in proteinuric kidney disease 5.
Hypokalemia risk: In the severe CKD subgroup (eGFR <30), the long-term safety data showed only 1% developed K+ <3.0 mmol/L and 5% had K+ 3.0-3.4 mmol/L over 12 months 6, 7. This low rate supports starting with standard dosing rather than a conservative approach.
Drug interactions: Administer other oral medications at least 2 hours before or after Lokelma 1.
Why This Matters for Outcomes
The 2025 European recommendations explicitly state that treatment to prevent recurrence should be initiated if there is no acute reversible factor 5. Your patient with advanced CKD has a non-reversible risk factor, and 43% of CKD patients experience hyperkalemia recurrence within 6-8 months 5. Starting with inadequate dosing risks:
- Delayed normalization
- Continued RAASi interruption (if applicable)
- Recurrent hyperkalemia episodes with associated cardiovascular morbidity
Real-world evidence demonstrates that patients with recurrent hyperkalemia have higher rates of major adverse cardiovascular events, hospitalization, and mortality 8. The standard 10 g TID dosing provides the most reliable path to rapid correction and sustained control.